JP2017524382A - 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ - Google Patents

偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ Download PDF

Info

Publication number
JP2017524382A
JP2017524382A JP2017526479A JP2017526479A JP2017524382A JP 2017524382 A JP2017524382 A JP 2017524382A JP 2017526479 A JP2017526479 A JP 2017526479A JP 2017526479 A JP2017526479 A JP 2017526479A JP 2017524382 A JP2017524382 A JP 2017524382A
Authority
JP
Japan
Prior art keywords
mrgprb2
mrgprx2
cells
antibody
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524382A5 (enExample
Inventor
シンチョン ドン，
シンチョン ドン，
ベンジャミン マクニール，
ベンジャミン マクニール，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2017524382A publication Critical patent/JP2017524382A/ja
Publication of JP2017524382A5 publication Critical patent/JP2017524382A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
JP2017526479A 2014-08-01 2015-07-31 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ Pending JP2017524382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462032350P 2014-08-01 2014-08-01
US62/032,350 2014-08-01
PCT/US2015/043116 WO2016019246A1 (en) 2014-08-01 2015-07-31 Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020099240A Division JP2020141708A (ja) 2014-08-01 2020-06-08 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ

Publications (2)

Publication Number Publication Date
JP2017524382A true JP2017524382A (ja) 2017-08-31
JP2017524382A5 JP2017524382A5 (enExample) 2018-09-13

Family

ID=55218352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526479A Pending JP2017524382A (ja) 2014-08-01 2015-07-31 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ
JP2020099240A Pending JP2020141708A (ja) 2014-08-01 2020-06-08 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020099240A Pending JP2020141708A (ja) 2014-08-01 2020-06-08 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ

Country Status (8)

Country Link
US (2) US10696971B2 (enExample)
EP (1) EP3174987B1 (enExample)
JP (2) JP2017524382A (enExample)
CN (1) CN107002087B (enExample)
AU (1) AU2015296135A1 (enExample)
CA (1) CA2957025A1 (enExample)
ES (1) ES2961366T3 (enExample)
WO (1) WO2016019246A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121802A (ko) * 2020-03-31 2021-10-08 재단법인 아산사회복지재단 Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법
JP2023546912A (ja) * 2020-10-21 2023-11-08 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレータ及び関連製品並びにその使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3040420A1 (en) * 2016-10-18 2018-04-26 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
CN111566215B (zh) * 2017-06-16 2024-06-04 约翰·霍普金斯大学 治疗g蛋白偶联受体介导的病症的组合物和方法
CN107142325A (zh) * 2017-06-28 2017-09-08 西安交通大学 一种用于药物类过敏反应敏感人群筛查的基因标志物及其应用
CN108398517A (zh) * 2018-02-11 2018-08-14 湖南正清制药集团股份有限公司 一种筛查正清风痛宁制剂中潜在致敏组分的方法
US20220227859A1 (en) 2019-05-16 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
CN110204607B (zh) * 2019-05-31 2021-04-20 西安交通大学 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用
CN110229228B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种对类过敏反应特异性受体mrgprx2蛋白的具有免疫原性的多肽及其应用
CN110204606B (zh) * 2019-05-31 2021-04-20 西安交通大学 一种用于制备兔多克隆抗体的多肽及其应用
CN110229227B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种用于制备elisa鼠单克隆包被抗体和兔多克隆检测抗体的多肽及其应用
CN110240643B (zh) * 2019-05-31 2021-05-28 西安交通大学 一种用于制备类过敏反应的双抗夹心试剂盒配对抗体的多肽及其应用
CN111500708A (zh) * 2020-05-08 2020-08-07 中南大学湘雅医院 一种与麻醉药物过敏相关分子标记及其应用和检测试剂盒
TW202229259A (zh) 2020-10-06 2022-08-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Mrgx2拮抗劑
CN119233829A (zh) 2022-03-31 2024-12-31 学校法人高崎健康福祉大学 用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物
WO2023230322A1 (en) * 2022-05-27 2023-11-30 Stealth Biotherapeutics Inc. Addressing injection site reactions associated with the administration of elamipretide
WO2024243490A2 (en) * 2023-05-25 2024-11-28 Stealth Biotherapeutics Inc. Methods for addressing injection site reactions associated with the administration of bevemipretide
CN116814689B (zh) * 2023-06-30 2024-04-05 海湃泰克(北京)生物医药科技有限公司 特异性表达hMRGPRX2的转基因小鼠的构建方法及其应用
CN116855503B (zh) * 2023-08-30 2023-12-08 上海益诺思生物技术股份有限公司 过表达mrgprx2的稳转细胞株及其构建方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118328A1 (ja) * 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited 脱顆粒抑制剤
JP2009060787A (ja) * 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
JP2011511622A (ja) * 2008-01-14 2011-04-14 プロビオドルグ エージー グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル
JP2012178985A (ja) * 2011-02-28 2012-09-20 Univ Of Tokyo 骨量増加剤のスクリーニング方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2001011022A1 (en) * 1999-08-05 2001-02-15 Smithkline Beecham Corporation Mouse g-protein coupled receptor edg3
WO2001016159A1 (en) * 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
US7510845B2 (en) * 2000-05-04 2009-03-31 California Institute Of Technology Assay employing G protein-coupled receptor expressed in dorsal root ganglia
JP2002355052A (ja) 2000-07-07 2002-12-10 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
EP1340979A3 (en) 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
WO2005028667A1 (ja) 2003-09-19 2005-03-31 Riken ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
JP2005304438A (ja) 2004-04-26 2005-11-04 Astellas Pharma Inc 新規スクリーニング方法
WO2007055823A2 (en) * 2005-10-28 2007-05-18 Multispan, Inc. Gpcr expressing cell lines and antibodies
WO2010065085A2 (en) * 2008-12-01 2010-06-10 The Johns Hopkins University Methods and compositions for treating or preventing pruritis
ES2659184T3 (es) * 2013-06-18 2018-03-14 Bayer Pharma Aktiengesellschaft Moduladores del receptor MRG

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118328A1 (ja) * 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited 脱顆粒抑制剤
JP2009060787A (ja) * 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
JP2011511622A (ja) * 2008-01-14 2011-04-14 プロビオドルグ エージー グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル
JP2012178985A (ja) * 2011-02-28 2012-09-20 Univ Of Tokyo 骨量増加剤のスクリーニング方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BBRC, vol. 349, JPN6019021054, 2006, pages 1322 - 1328, ISSN: 0004207791 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 45, JPN6019021055, 2003, pages 44400 - 44404, ISSN: 0004207792 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121802A (ko) * 2020-03-31 2021-10-08 재단법인 아산사회복지재단 Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법
KR102494928B1 (ko) 2020-03-31 2023-02-03 재단법인 아산사회복지재단 Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법
JP2023546912A (ja) * 2020-10-21 2023-11-08 エサイエント ファーマシューティカルズ，インコーポレイティド Ｍａｓ関連ｇタンパク質受容体ｘ２のモジュレータ及び関連製品並びにその使用
US12384748B2 (en) 2020-10-21 2025-08-12 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor X2 and related products and methods

Also Published As

Publication number Publication date
ES2961366T3 (es) 2024-03-11
CA2957025A1 (en) 2016-02-04
AU2015296135A1 (en) 2017-02-16
EP3174987B1 (en) 2023-10-11
CN107002087A (zh) 2017-08-01
CN107002087B (zh) 2021-09-28
US20200370051A1 (en) 2020-11-26
US10696971B2 (en) 2020-06-30
JP2020141708A (ja) 2020-09-10
US20170204419A1 (en) 2017-07-20
WO2016019246A1 (en) 2016-02-04
EP3174987A1 (en) 2017-06-07
EP3174987A4 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
US20200370051A1 (en) Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
US20230228738A1 (en) Compositions and methods for treating g protein coupled receptor mediated conditions
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
CN104602708A (zh) 痴呆症治疗药或预防药
US20220313789A1 (en) Targeting melanocortin 3 receptor for treatment/prevention of eating, metabolism, and/or emotional disorders
TW201307385A (zh) 胃腸炎症和銀屑病以及哮喘的治療
JP2022512735A (ja) 肝疾患を治療するための組成物および方法
WO2023143425A1 (zh) 改善认知障碍的方法
DK2904009T3 (en) RELATIONSHIPS FOR TREATING THE REMYELINIZATION BLOCK IN DISEASES RELATED TO THE EXPRESSION OF HERV-W COAT PROTEIN
JP2010532334A (ja) 腎疾患を処置するための化合物および方法
CN102741277A (zh) 在治疗运动神经元疾病中的IFNγ抑制剂
US20220072101A1 (en) Harnessing inflammation to treat neurodevelopmental disorders
EP3916015A1 (en) Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
BRPI0617297A2 (pt) composiÇÕes e mÉtodos para tratamento de hipersecreÇço das vias aÉreas
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
JP2018508564A (ja) 骨関節炎処置を治療目的としたＣｏｌｌ２−１ペプチド及びそのニトロ化形態

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200206